Eli Lilly and Co at Goldman Sachs Global Healthcare Conference Transcript
Okay. Great. I think we're going to get started. Thanks so much for joining us for the afternoon session. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs. We're very pleased to have Eli Lilly with us this afternoon. Joining us from the company is Josh Smiley, CFO. Josh, thanks very much for taking the time.
Thanks for having us.
Questions & Answers
Maybe just to get started, big picture, given your background and experience, would just kind of love to hear your thoughts on this question about broader industry consolidation. There's been consolidation in the payer-provider side now over the last couple of years. We saw another large transaction earlier this year in the biopharma space. So do you think this is the start of a trend here in the biopharma space in response to kind of the payer-provider
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |